NasdaqGS - Nasdaq Real Time Price USD

Milestone Pharmaceuticals Inc. (MIST)

Compare

1.8000

+0.0850

(+4.96%)

At close: December 20 at 4:00:03 PM EST

1.8800

+0.08

(+4.44%)

After hours: December 20 at 5:56:18 PM EST

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

MONTREAL and CHARLOTTE, N.C., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, and Chief Commercial Officer, Lorenz Muller, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30 a.m. Eastern Time. A live webcast of the fireside chat will be available to conference participants. If you are interested in viewing the fireside chat or meeting with the

GlobeNewswire 27 days ago

MIST
+4.96%
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Zacks last month

MIST
+4.96%
Milestone Pharmaceuticals: Q3 Earnings Snapshot

MONTREAL (AP) — Milestone Pharmaceuticals Inc. MIST) on Tuesday reported a loss of $9.4 million in its third quarter. The Montreal-based company said it had a loss of 14 cents per share.

Associated Press Finance last month

MIST
+4.96%
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. “Our primary focus at Milestone is preparing for potential FDA approval of CARDAMYST (etripamil) nasal spray for the management of PSVT,” said Joseph Oliveto, President and Chief Executive Officer of Mileston

GlobeNewswire last month

MIST
+4.96%
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%

Key Insights The considerable ownership by individual investors in Milestone Pharmaceuticals indicates that they...

Simply Wall St. 2 months ago

MIST
+4.96%
Milestone Pharmaceuticals to Host Investor KOL Event

Learnings from the Field: Managing PSVT and Studying AFib-RVR in the Community Setting Hosted 10 am ET, Tuesday, October 8, 2024 MONTREAL and CHARLOTTE, N.C., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will host Part 2 of its virtual investor education series on Tuesday, October 8, 2024 from 10:00 AM ET to 11:30 AM ET. To

GlobeNewswire 2 months ago

MIST
+4.96%
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline results from a multi-center, randomized, double-blind, placebo-controlled trial in China evaluating the efficacy and safety of etripamil nasal spray in paroxysmal supraventricu

GlobeNewswire 3 months ago

MIST
+4.96%
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors (“Board”), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, tran

GlobeNewswire 3 months ago

MIST
+4.96%
CADL

EBS
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MONTREAL and CHARLOTTE, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the H.C. Wainwright 26th Annual Global Investment Conference, to take place from September 9-11, 2024, in New York City. The Fireside Chat will be on September 10th at 2 PM EDT. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section

GlobeNewswire 3 months ago

MIST
+4.96%
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

MONTREAL and CHARLOTTE, N.C., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an upcoming data presentation on etripamil at the annual meeting of the European Society of Cardiology, ESC Congress 2024 in London, United Kingdom on August 30, 2024. Professor John Camm will present patient reported outcomes data from the NODE-303 Phase

GlobeNewswire 3 months ago

MIST
+4.96%
Milestone Pharmaceuticals: Q2 Earnings Snapshot

MONTREAL (AP) — Milestone Pharmaceuticals Inc. MIST) on Thursday reported a loss of $9.4 million in its second quarter. The Montreal-based company said it had a loss of 14 cents per share.

Associated Press Finance 4 months ago

MIST
+4.96%
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed as Independent Board Directors MONTREAL and CHARLOTTE, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the second quarter ended June 30, 2024 and provided a regulatory and corporate update. “The FDA acceptance of our New Drug

GlobeNewswire 4 months ago

MIST
+4.96%
Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference

MONTREAL and CHARLOTTE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will participate in the BTIG Virtual Biotechnology Conference, to take place from August 5-6, 2024. The presentation will be in the form of a Fireside Chat to take place on August 6th at 8 AM EDT. The webcast will be available to watch both live and as a replay for approximately 90 days following the presentation in the News & Events

GlobeNewswire 4 months ago

MIST
+4.96%
Milestone Pharmaceuticals Refreshes Board of Directors

– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (“Milestone” or the “Company”), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced steps to refresh its Board of Directors (“Board”). Stuart Duty and Andrew Saik ha

GlobeNewswire 5 months ago

EYPT

ACHV

MIST
+4.96%
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

MONTREAL and CHARLOTTE, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will host Part I of its virtual investor educational series on Thursday, June 20, 2024, at 8:00 AM ET. To register for “Learnings from the Field: Expert Perspectives on Managing PSVT in the Community Setting,” click here. The event will feature Geo

GlobeNewswire 6 months ago

MIST
+4.96%
It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put Under The Microscope

Key Insights Milestone Pharmaceuticals' Annual General Meeting to take place on 13th of June Total pay for CEO Joe...

Simply Wall St. 6 months ago

MIST
+4.96%
Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held in New York City, NY from June 4-6, 2024. Management will participate in a Fireside Chat on June 6th at 11:30 AM EDT. The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milest

GlobeNewswire 6 months ago

MIST
+4.96%
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the United States Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) on May 26, 2024 for CARDAMYST (etripamil) nasal spray, its lead investigational product for the management of paroxysmal supraventricular tachycardi

GlobeNewswire 6 months ago

MIST
+4.96%
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

SVT Awareness Day to be held on Wednesday June 5, 2024MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT). SVT Awareness Day will be held on Wednesday June 5, 2024, during World Heart Rhythm Week (June 4-10), t

GlobeNewswire 6 months ago

MIST
+4.96%
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know

Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 7 months ago

MIST
+4.96%

Performance Overview

Return	MIST	S&P 500
YTD	+7.78%	+24.34%
1-Year	-36.95%	+24.38%
3-Year	-72.14%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Milestone Pharmaceuticals Inc. (MIST)

Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference

After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright

Milestone Pharmaceuticals: Q3 Earnings Snapshot

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%

Milestone Pharmaceuticals to Host Investor KOL Event

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024

Milestone Pharmaceuticals: Q2 Earnings Snapshot

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference

Milestone Pharmaceuticals Refreshes Board of Directors

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

It Looks Like Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO May Expect Their Salary To Be Put Under The Microscope

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know

Performance Overview